A 7-year-old girl presents with polyuria and weight loss; across the corridor, a 5-year-old boy has just experienced his second unprovoked seizure. These scenarios represent two of the most prevalent chronic conditions in paediatric medicine. affects approximately 215,000 children under 15 years globally, with UK incidence rising at 3-4% annually. has even greater reach, affecting 1 in 200 children, making it the most common serious neurological condition in paediatrics. Understanding their epidemiology shapes service provision, family support, and long-term outcome planning.
Type 1 Diabetes (T1D): Autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency
Epilepsy: Recurrent tendency to unprovoked seizures (≥2 unprovoked seizures >24 hours apart, or 1 seizure with high recurrence risk)
| Parameter | Type 1 Diabetes | Epilepsy |
|---|---|---|
| UK Prevalence | 2 per 1,000 children | 5-10 per 1,000 children |
| Annual Incidence | 24.5 per 100,000 | 60 per 100,000 |
| Median Age at Diagnosis | 10-14 years | 5-6 years |
| Male:Female Ratio | 1:1 | 1.2:1 |
📌 Mnemonic for T1D Presentation: The 4 T's - Toilet (polyuria), Thirsy (polydipsia), Tired (lethargy), Thinner (weight loss)

The pathogenesis of involves genetic susceptibility (HLA-DR3/DR4 haplotypes confer 50% risk), environmental triggers (viral infections, dietary factors), and immune dysregulation leading to insulitis. β-cell destruction occurs over months to years, with clinical presentation when 80-90% are destroyed. In contrast, represents diverse mechanisms: ion channelopathies (SCN1A mutations in Dravet syndrome), structural abnormalities (cortical dysplasia), or acquired insults (hypoxic-ischemic injury). The final common pathway is neuronal hyperexcitability from imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission.
T1D Pathophysiology:
Epilepsy Pathophysiology:
| Mechanism | Type 1 Diabetes | Epilepsy |
|---|---|---|
| Primary Defect | Autoimmune β-cell destruction | Neuronal hyperexcitability |
| Key Molecules | Insulin, C-peptide, autoantibodies | Glutamate, GABA, ion channels |
| Onset Pattern | Subacute (weeks-months) | Variable (acute to chronic) |
| Reversibility | Irreversible | Potentially reversible (60-70%) |

A 9-year-old presents with 3-week history of excessive thirst, nocturia, and 4kg weight loss. Random glucose is 18.2 mmol/L; venous pH 7.32, ketones 3.8 mmol/L. NICE NG18 guides immediate management: confirm diabetes (HbA1c ≥48 mmol/mol or fasting glucose ≥7.0 mmol/L), assess for DKA (pH <7.3 or bicarbonate <15 mmol/L), and initiate insulin therapy within 24 hours. Meanwhile, a 6-year-old experiences a 90-second episode of staring, unresponsiveness, and lip-smacking. Witnessed second episode 3 weeks later. NICE NG217 recommends specialist assessment within 2 weeks for first unprovoked seizure, EEG within 4 weeks, and neuroimaging (MRI preferred) to identify structural causes.
T1D Diagnostic Criteria (WHO):
DKA Assessment (NICE NG18):
Epilepsy Diagnosis (NICE NG217):
| Investigation | Type 1 Diabetes | Epilepsy |
|---|---|---|
| First-line | Random/fasting glucose, HbA1c | EEG (awake and sleep) |
| Confirmatory | C-peptide, autoantibodies | Video-EEG telemetry |
| Imaging | Not routine (consider if atypical) | MRI brain (all first seizures) |
| Timeframe | Same-day assessment | Specialist within 2 weeks |
🚩 Red Flag: In suspected DKA, never give insulin bolus without IV fluids first-risks cerebral edema from rapid osmotic shifts.

Both conditions present diagnostic challenges. New-onset T1D can mimic urinary tract infection (polyuria), eating disorders (weight loss), or behavioral problems (irritability). Key discriminator: random glucose >11.1 mmol/L is diagnostic; urinalysis showing glycosuria without infection confirms suspicion. Epilepsy diagnosis requires distinguishing seizures from syncope (gradual vs. sudden onset, prolonged vs. brief loss of consciousness), breath-holding spells (cyanosis, triggered by distress), or parasomnias (occur from sleep, stereotyped movements). EEG epileptiform discharges (sensitivity 50% first recording, 80-90% with repeat sleep-deprived studies) provide objective evidence, but normal EEG doesn't exclude epilepsy-diagnosis remains clinical.
T1D Differential Diagnosis:
Epilepsy Differential Diagnosis:
| Feature | Seizure | Syncope |
|---|---|---|
| Onset | Sudden, no warning | Gradual, prodrome common |
| Duration | 1-3 minutes | <30 seconds |
| Color Change | Cyanosis possible | Pallor typical |
| Postictal State | Confusion 5-15 minutes | Rapid full recovery |
| Injury Risk | High (falls, tongue-biting) | Lower (gradual collapse) |
⭐ Clinical Pearl: C-peptide <200 pmol/L distinguishes T1D from T2D (preserved in T2D). In epilepsy, prolactin rises 10-20 minutes post-seizure (not in psychogenic seizures), but short half-life limits clinical utility.
NICE NG18 mandates multiple daily injection (MDI) regimen or continuous subcutaneous insulin infusion (CSII/pump) for all children with T1D. Initial total daily dose: 0.5-1.0 units/kg/day, split 50% basal (once-daily long-acting analog: glargine, detemir, degludec) and 50% bolus (rapid-acting analog: lispro, aspart, glulisine) with meals using carbohydrate counting (1 unit per 10-15g carbohydrate). Target HbA1c ≤48 mmol/mol without disabling hypoglycemia. Continuous glucose monitoring (CGM) or flash glucose monitoring recommended for all. management follows NICE NG217: first-line monotherapy based on seizure type-sodium valproate for generalized seizures (contraindicated in females of childbearing potential due to teratogenicity), carbamazepine or lamotrigine for focal seizures. Start low, titrate slowly to minimize adverse effects. Target: seizure freedom with minimal side effects. Aim for monotherapy; if ineffective after 2 appropriate trials, refer to tertiary epilepsy center.
T1D Insulin Regimens:
Epilepsy First-Line Medications (NICE NG217):
| Medication | Starting Dose | Target Dose | Key Adverse Effects |
|---|---|---|---|
| Carbamazepine | 5 mg/kg/day | 10-20 mg/kg/day | Rash, hyponatremia, diplopia |
| Lamotrigine | 0.5 mg/kg/day | 1-5 mg/kg/day | Stevens-Johnson syndrome (slow titration essential) |
| Sodium Valproate | 10 mg/kg/day | 20-30 mg/kg/day | Weight gain, tremor, teratogenicity |
| Levetiracetam | 10 mg/kg/day | 20-40 mg/kg/day | Behavioral changes, somnolence |
⚠️ Warning: Never abruptly stop anti-epileptic drugs-risks rebound seizures and status epilepticus. Taper over 2-3 months minimum.
A 14-year-old with T1D presents with recurrent severe hypoglycemia (glucose <3.0 mmol/L) despite optimized insulin regimen. Investigations reveal hypoglycemia unawareness (loss of autonomic warning symptoms) and impaired counter-regulatory response. Management requires technology integration: emphasizes hybrid closed-loop systems (automated insulin delivery adjusted by CGM readings) reducing hypoglycemia by 40% versus standard therapy. Simultaneously, structured education addressing hypoglycemia fear and glucose variability is essential. In epilepsy, drug-resistant epilepsy (failure of 2 appropriate medications) affects 30% of children. guidelines recommend early tertiary referral for video-EEG telemetry, advanced neuroimaging (3T MRI with epilepsy protocol), and consideration of epilepsy surgery (temporal lobectomy achieves 60-80% seizure freedom in mesial temporal sclerosis), vagal nerve stimulation, or ketogenic diet (50% responder rate in drug-resistant cases).
T1D Special Populations:
Epilepsy Complications:
| Complication | Type 1 Diabetes | Epilepsy |
|---|---|---|
| Acute Life-Threatening | DKA (1-2% annual risk) | Status epilepticus (5% lifetime risk) |
| Chronic Morbidity | Retinopathy, nephropathy (rare <10 years) | Cognitive impairment (30-40%) |
| Mortality | 0.1-0.2 per 1,000 person-years | 1.2 per 1,000 person-years |
| Quality of Life Impact | High (daily management burden) | Moderate (driving restrictions, injury risk) |
💎 Clinical Pearl: In drug-resistant epilepsy, early surgical evaluation is critical-outcomes are best when surgery occurs within 2 years of diagnosis, before secondary generalization develops.
Key Take-Aways:
Essential Chronic Paediatric Conditions Numbers:
| Parameter | Value | Clinical Significance |
|---|---|---|
| T1D HbA1c Target | ≤48 mmol/mol | Balance glycemic control with hypoglycemia risk |
| DKA Definition | pH <7.3 + ketones >3.0 mmol/L | Requires immediate hospital admission |
| Hypoglycemia Threshold | <3.0 mmol/L | Treat with 15g fast-acting carbohydrate |
| Epilepsy Drug Failure | 2 appropriate trials | Defines drug-resistant epilepsy |
| Status Epilepticus | Seizure >5 minutes | Emergency requiring benzodiazepine |
| SUDEP Risk | 1:4,500 child-years | Counsel families on seizure control importance |
Key Principles:
Quick Reference:
| Condition | Emergency Management | Monitoring | Long-term Target |
|---|---|---|---|
| T1D DKA | 10 mL/kg 0.9% saline, then insulin 0.05-0.1 units/kg/hr | Hourly glucose, 2-hourly venous gas | Resolution: pH >7.3, ketones <0.6 mmol/L |
| Hypoglycemia | 15g glucose, repeat in 15 min if needed | CGM/flash monitoring | Time in range 70-180 mg/dL >70% |
| Status Epilepticus | Buccal midazolam 0.5 mg/kg (max 10 mg) | Seizure diary, medication adherence | Seizure freedom |
| Drug-Resistant Epilepsy | Tertiary referral after 2 failed medications | Video-EEG telemetry, 3T MRI | Consider surgery/VNS/ketogenic diet |
Test your understanding with these related questions
A 8-year-old child presents with fever, irritability, and a widespread petechial rash that doesn't blanch with pressure. The child appears unwell and has neck stiffness. What is the most appropriate immediate management?
Get full access to all lessons, practice questions, and more.
Start Your Free Trial